MAP2K7 and hepatocellular carcinoma: Nine of 26 HCC patients with detectable mutations in ctDNA (34.6%) had mutations in the Wnt/β‐catenin signaling pathway, and three (11.5%) had mutations in the RAF/MEK/ERK signaling pathway (Fig. 1B).